U.S. License Holder:
ImClone
Date of License:
February-12-2004
Last Update:
Dec-15-2024
FDA-Approved Indications
ERBITUX (cetuximab) is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:
Head and Neck Cancer: Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy; Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil; Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy;
Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test: in combination with FOLFIRI for first-line treatment; in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy; as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan;
BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC): In combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.